GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq
29. September 2020 14:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Sept. 29, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies...
GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market
04. Juni 2020 11:00 ET
|
GeoVax, Inc.
ATLANTA, GA, June 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases...
GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update
06. Mai 2020 09:00 ET
|
GeoVax, Inc.
Progress on COVID-19 Vaccine Development; Continued Advancements in Other Infectious Disease and Immuno-Oncology Programs ATLANTA, GA, May 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax...
GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act
30. März 2020 09:00 ET
|
GeoVax, Inc.
Company Ready to Advance COVID-19 Vaccine Candidates to Animal Efficacy Testing, Manufacturing Scale-Up, and Human Clinical Trials ATLANTA, GA, March 30, 2020 (GLOBE NEWSWIRE) -- via...
Update: GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
06. Februar 2020 11:49 ET
|
GeoVax, Inc.
Company Comments on NIH/NIAID Discontinuance of Sanofi/GSK HVTN 702 Trial ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX) (OTC: GOVXD), a...
GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
06. Februar 2020 09:00 ET
|
GeoVax, Inc.
Company Comments on NIH/NIAID Discontinuance of Sanofi/GSK HVTN 702 Trial ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology...
GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine
27. Januar 2020 10:18 ET
|
GeoVax, Inc.
ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVXD), a biotechnology company developing human immunotherapies and vaccines against...
GeoVax Observes 2019 World AIDS Day
02. Dezember 2019 09:00 ET
|
GeoVax, Inc.
Developing Multiple Strategies Toward Ending the HIV/AIDS Epidemic ATLANTA, GA, Dec. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company...
GeoVax Presents HIV Vaccine Study Data
24. Juli 2019 09:00 ET
|
GeoVax, Inc.
Presentation Made at the 10th International AIDS Society Conference on HIV Science ATLANTA, GA, July 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a...
GeoVax Announces Upcoming Presentation of Lassa Fever Vaccine Data
16. Juli 2019 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, July 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that Senior...